Scholar Rock Holding Corp (SRRK) director Srinivas Akkaraju reported purchases totaling 289,470 common shares held by Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P. The purchases occurred October 23 and October 26, 2026, at reported weighted-average prices of $41.31, $41.82 and $41.59 per share. No Rule 10b5-1 plan is reported. A separate entry lists 27,971 common shares held directly as of October 23, 2026.
Scholar Rock Holding Corp. (SRRK) director Katie Peng filed a notice of a proposed sale of 1,006 common shares, with an aggregate market value of $48,610 and an approximate sale date of October 1, 2026. J.P. Morgan Securities LLC is listed as broker. The notice lists 261 shares from an RSU transaction dated August 15, 2026, and 745 shares from an RSU transaction dated September 15, 2026.
Keith Woods, Chief Operating Officer of Scholar Rock Holding Corp (SRRK), transferred 48,034 shares of common stock as a gift to the RKW Irrevocable Trust on September 24, 2026, for no consideration; his spouse serves as trustee. The reported position following the transaction lists 0 common shares, 122,021 RSUs subject to time-based vesting conditions, and 450,000 RSUs subject to performance- and time-based vesting conditions. Woods disclaimed beneficial ownership of the trust shares except to the extent of his pecuniary interest. No Rule 10b5-1 plan is reported.
Scholar Rock Holding Corp (symbol: SRRK) is the issuer of record for a Form 4 filing submitted to the SEC. Hallal David reported disposition transactions in this Form 4 filing.
Scholar Rock Holding Corp (SRRK) Chief Executive Officer David Hallal transferred 36,652 common shares to The Hallal Family Irrevocable Trust-2021 on September 21, 2026, for no consideration. Hallal's reported post-transaction position was 1,602,382, comprising common stock and RSUs. The Hallal Family Irrevocable Trust-2021 reported 36,652 shares, while The Hallal Family Irrevocable Trust-2012 held 205,000 shares.
Scholar Rock Holding Corp (SRRK) reported that the U.S. Food and Drug Administration has approved ISEMBYLD™ (apitegromab-mstn) for the treatment of spinal muscular atrophy in adults and children 2 years of age and older who are receiving a survival motor neuron 2 (SMN2)-targeted treatment. The company clarified remarks made during an investor call, where management had incorrectly stated that the FDA did not require post-marketing safety commitments for bone or reproductive safety. Scholar Rock disclosed that, as part of the approval, the FDA imposed a post-marketing requirement to establish a pregnancy safety study to collect and analyze data on pregnancy complications and birth outcomes in exposed pregnancies, and also requested submission of all serious and non-serious domestic and foreign fracture cases as 15-day “alert reports.” Scholar Rock stated its intention to conduct this study and submit these reports in accordance with the FDA’s request.
Scholar Rock Holding Corp (SRRK) reports that the U.S. FDA has approved ISEMBYLD™ (apitegromab-mstn) as a treatment for spinal muscular atrophy (SMA) in adults and children 2 years and older who are already receiving an SMN2‑targeted therapy. ISEMBYLD is described as the first and only muscle‑targeted treatment to show motor function improvement in this population.
The approval is supported by the Phase 3 SAPPHIRE trial, where patients receiving ISEMBYLD plus SMN2‑targeted treatment had a 2.2‑point improvement on the HFMSE scale compared with SMN2‑targeted treatment alone at one year and a higher proportion achieving ≥3‑point motor function gains. Scholar Rock also received a Rare Pediatric Disease Priority Review Voucher and is preparing a U.S. commercial launch, including patient support services and coordination with payers. A conference call and webcast on September 14, 2026, will discuss the approval.
Scholar Rock Holding Corporation received an updated Schedule 13G/A from investment manager Redmile Group, LLC, individual filer Jeremy C. Green, and RedCo II Master Fund, L.P.. Redmile and Green report beneficial ownership of 4,311,092 shares of Scholar Rock common stock, representing 3.6% of the class.
All 4,311,092 shares are held by investment vehicles managed by Redmile, and both Redmile and Green report shared voting and dispositive power over these shares, with no sole voting or dispositive power. The ownership percentage is based on 119,828,338 shares outstanding as of May 4, 2026. RedCo II Master Fund, L.P. reports 0 shares and 0.0% ownership. Redmile and Green each disclaim beneficial ownership except to the extent of their pecuniary interest.
Scholar Rock Holding Corporation received an amended Schedule 13G filing showing that Invus Public Equities, L.P. and related entities collectively report beneficial ownership of 9,575,013 shares of common stock. Based on 119,828,338 shares outstanding as of May 4, 2026, this represents 8.0% of Scholar Rock’s common stock. The Invus structure runs through Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., and ultimately to Raymond Debbane, each of whom may be deemed to beneficially own the same block of shares through their control relationships. The reporting group states the shares were not acquired for the purpose of changing or influencing control of Scholar Rock, consistent with passive investment status under Schedule 13G.
Scholar Rock Holding Corporation described an update to its existing at-the-market offering program. The company filed a new prospectus supplement under its shelf registration statement on Form S-3ASR, allowing it to offer and sell, from time to time at its sole discretion through Jefferies LLC as sales agent, additional shares of common stock with an aggregate offering price of up to $200,000,000.
This new prospectus supplement replaces and supersedes the prior prospectus supplement dated November 14, 2025, and the offering pursuant to that prior supplement has been terminated. To date, the company has generated approximately $257.7 million in net proceeds from sales of common stock under the at-the-market program. Legal opinions and related consents from Goodwin Procter LLP are included as exhibits.
Scholar Rock Holding Corporation is adding capacity under its existing Open Market Sale agreement with Jefferies LLC to sell up to $200,000,000 of common stock in an at-the-market offering. This prospectus supplement resets the remaining availability under the sales agreement to $200,000,000 and replaces a prior supplement.
Sales will be made from time to time through Jefferies, acting as sales agent, with compensation of up to 3.0% of gross proceeds. The company had 121,600,396 shares outstanding as of June 30, 2026; an illustrative scenario assumes 4,362,050 shares sold at $45.85 per share. After such sales, adjusted net tangible book value would rise from $2.09 to $3.55 per share, implying dilution of $42.30 per share to new investors.
Net proceeds, together with existing cash, cash equivalents and investments, are intended to support commercialization of apitegromab, advance ongoing and future clinical programs, further develop the company’s TGFβ-based platform and pipeline, and for working capital and general corporate purposes. Scholar Rock is a late-stage biopharmaceutical company focused on neuromuscular diseases; its lead antibody apitegromab for spinal muscular atrophy has a resubmitted BLA under FDA priority review with a September 30, 2026 PDUFA action date and an MAA under review in Europe.